Rise in Incidences of Congestive Heart Failure Drive the Global Cardiomyopathy Market

Global cardiomyopathy market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024–2031). Cardiomyopathy refers to a heart disease that causes hindrances in pumping blood to the rest of the body. It can also lead to some other serious heart conditions. Common causes of cardiopathy include autoimmune diseases, infections, endocrine diseases, neuromuscular disorders, nutritional deficiency, and over-exposure to toxins such as alcohol. The market growth is driven by the advancements in understanding and managing cardiomyopathy and a rise in incidences of congestive heart failure, coronary heart disease, and heart attack. 

Browse the full report description of “Cardiomyopathy Market Size, Share & Trends Analysis Report by Type (Dilated Cardiomyopathy, Restrictive Cardiomyopathy, Unclassified Cardiomyopathy, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Dysplasia), by Diagnosis Test (Blood Tests, Cardiac MRI, Chest X-Ray, Cardiac CT Scan, Echocardiogram, Treadmill Stress Test, Electrocardiogram (ECG), Cardiac Catheterization, Genetic Testing or Screening) by Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery) and by End-User (Homecare, Hospitals and Clinics, Diagnostic Center, and Other) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/cardiomyopathy-market

Recent Developments

• In June 2024, Alnylam Pharmacuticals, Inc. announced positive topline results from the HELIOS-B Phase 3 study of Vutrisiran. It achieved 28.0% and 33.0% reduction in composite mortality and recurrent cardiovascular events in the overall and monotherapy populations.

• In March 2023, Ionics Pharmaceuticals, Inc. announced the evaluation of Eplontersen for CARDIO-TTRansform Phase III trial for transthyretin-mediated amyloid cardiomyopathy, a systemic, progressive, and fatal condition that typically leads to progressive heart failure and often mortality within three to five years from disease onset.

Market Coverage  

· The market number available for 2023-2031 

· Base year: 2023 

· Forecast period: 2024-2031 

· Segment Covered- 

o By Type

o By Diagnosis Test

o By Treatment

o By End-user

· Regions Covered- 

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World

• Competitive Landscape- Amgen Inc., Bristol-Myers Squibb (BMS), Merck Group, Novartis Pharma AG, and Pfizer Inc. among others.

Key questions addressed by the report 

• What is the market's growth rate? 
• Which segment and region dominate the market in the base year? 
• Which segment and region will project the fastest growth in the market? 
• Who is the leader in the market? 
• How are players addressing challenges to sustain growth? 
• Where is the investment opportunity? 

Global Cardiomyopathy Market Report Segment 

By Type

• Dilated Cardiomyopathy
• Restrictive Cardiomyopathy
• Unclassified Cardiomyopathy
• Hypertrophic Cardiomyopathy
• Arrhythmogenic Right Ventricular Dysplasia

By Diagnosis Test

• Blood Tests
• Cardiac MRI
• Chest X-Ray
• Cardiac CT scan
• Echocardiogram
• Treadmill Stress Test
• Electrocardiogram (ECG)
• Cardiac Catheterization
• Genetic Testing or Screening

By Treatment

• Medication
• Surgically Implanted Devices

• Nonsurgical Procedures

• Septal Ablation
• Radiofrequency Ablation

• Surgery

• Septal Myectomy
• Heart Transplant

By End-user

• Homecare
• Hospitals and Clinics
• Diagnostic Center
• Other (Ambulatory Surgical Centers (ASCs)

Global Cardiomyopathy Market Report Segment by Region 

North America 

· United States 

· Canada 

Europe 

· UK 

· Germany 

· Italy 

· Spain 

· France 

· Rest of Europe 

Asia-Pacific 

· China 

· India 

· Japan 

· South Korea 

· Rest of Asia-Pacific 

Rest of the World 

· Latin America

· Middle East and Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiomyopathy-market